Overview

Tricaprilin Phase 2 Pilot Study in Migraine

Status:
Active, not recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This is a randomised, double-blind, placebo-controlled, parallel-group, multi-centre study of tricaprilin as AC-SD-03 compared with placebo for the reduction of migraine in participants with frequent migraine.
Phase:
Phase 2
Details
Lead Sponsor:
Cerecin